Literature DB >> 1353506

The influence of different beta-blocking drugs on the peripheral circulation in Raynaud's phenomenon and in hypertension.

C Franssen1, H Wollersheim, A de Haan, T Thien.   

Abstract

In a double-blind, randomized, placebo-controlled study, the authors investigated the effects of different beta-adrenoceptor blocking drugs on the peripheral circulation. A single intravenous injection of the nonselective beta-blocker propranolol (0.20 mg/kg), the beta 1-selective adrenoceptor blocker metoprolol (0.25 mg/kg), and the nonselective beta-blocker with partial agonistic activity (PAA) pindolol (0.04 mg/kg) and of placebo (saline) was given to eight patients with a primary Raynaud's phenomenon and to nine untreated patients with primary hypertension. The authors measured finger skin temperature (FST), and laser Doppler estimated finger skin blood flux (LDF) before, during, and after a standardized finger cooling test, performed 25 minutes after the administration of the drugs. In both patients groups propranolol, metoprolol, and pindolol had no significant effect on FST and LDF in the first 25 minutes after administration both in comparison to baseline value and to placebo. Also, no significant differences were found in the recoveries of FST and LDF after cold challenge between all drugs and placebo in both groups. The authors conclude that no adverse effect of any type of beta-adrenoceptor blocker in comparison to placebo could be detected after a single administration on both the baseline finger skin perfusion and the recovery after cold-induced vasoconstriction. In addition, the authors could not demonstrate a favorable effect of beta 1-selectivity or PAA in comparison to a nonselective beta-adrenoceptor blocker without PAA, in any group.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353506     DOI: 10.1002/j.1552-4604.1992.tb05777.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

1.  Development of a questionnaire to assess 'Hie' symptoms using an evidence-based analysis.

Authors:  Takeaki Takeuchi; Mutsuhiro Nakao; Michitaka Kohno; Minoru Hatano; Masanori Niimi; Eiji Yano
Journal:  Environ Health Prev Med       Date:  2008-09-19       Impact factor: 3.674

2.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

3.  Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.

Authors:  R D Feldman; N R Campbell; P Larochelle
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

4.  1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension.

Authors:  R D Feldman; N Campbell; P Larochelle; P Bolli; E D Burgess; S G Carruthers; J S Floras; R B Haynes; G Honos; F H Leenen; L A Leiter; A G Logan; M G Myers; J D Spence; K B Zarnke
Journal:  CMAJ       Date:  1999       Impact factor: 8.262

Review 5.  Peripheral vasoconstriction induced by β-adrenoceptor blockers: a systematic review and a network meta-analysis.

Authors:  Charles Khouri; Thomas Jouve; Sophie Blaise; Patrick Carpentier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-05-31       Impact factor: 4.335

Review 6.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

Review 7.  Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma.

Authors:  David C Broadway; Heidi Cate
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

8.  Clinical data mining related to the Japanese kampo concept "hie" (oversensitivity to coldness) in men and pre- and postmenopausal women.

Authors:  H Tokunaga; K Munakata; K Katayama; R Yamaguchi; S Imoto; S Miyano; K Watanabe
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-24       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.